Sepracor, Inc. NASDAQ: SEPR is a pharmaceutical company founed in 1984 and located in Marlborough, Massachusetts. The company's primary focus is on products for the treatment of central nervous system and respiratory disorders. The primary source of its revenue is the approximately $600 million annually from its Xopenex franchise of drugs, available as a multi-dose inhaler (MDI) or nebulized (UDV) form. However, the blockbuster insomnia drug Lunesta, which was approved by the FDA in December, 2004 and launched in April of 2005, is on pace to exceed $1 billion in annual sales. In addition, on February 13, 2006, Sepracor filed a new drug application (NDA) for Brovana to treat Chronic Obstructive Pulmonary Disease (COPD).